Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say
Executive Summary
Pharmaceutical industry officials are promoting the idea of “marrying” the concepts of performance-based approaches and process analytical technology in the draft ICH Q12 guideline. Embedding this idea in ICH Q12 would give industry more flexibility in managing post-approval changes and aligns with the guideline’s concept of lifecycle improvement.
You may also be interested in...
Removal Of ‘Legal’ And ‘Implicit’ Terms Cleared Way For ICH Q12 Guideline
Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.
Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision
FDA commissioner discloses effort underway to tighten oversight of changes to active pharmaceutical ingredient manufacturing processes by rewriting parts of its drug GMP regulation.
Pharma Sector Explores How To Embrace The Fourth Industrial Revolution
While many in the pharmaceutical sector pay lip service to the digital industrial revolution called 4.0, few have embraced it. But that could be about to change.